{
    "id": 2881,
    "fullName": "POLB loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "POLB loss indicates loss of the POLB gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5423,
        "geneSymbol": "POLB",
        "terms": [
            "POLB"
        ]
    },
    "variant": "loss",
    "createDate": "01/05/2015",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1583,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, POLB-deficient cells had increased sensitivity to Veliparib (ABT-888) in cell culture compared to cells with wild-type POLB (PMID: 24770870)",
            "molecularProfile": {
                "id": 2705,
                "profileName": "POLB loss"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1581,
                    "pubMedId": 24770870,
                    "title": "Base excision repair defects invoke hypersensitivity to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24770870"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1582,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PolB deficient cells had increased sensitivity to Lynparza (olaparib) in cell culture compared to cells with wild-type PolB (PMID: 24770870).",
            "molecularProfile": {
                "id": 2705,
                "profileName": "POLB loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1581,
                    "pubMedId": 24770870,
                    "title": "Base excision repair defects invoke hypersensitivity to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24770870"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2705,
            "profileName": "POLB loss",
            "profileTreatmentApproaches": [
                {
                    "id": 4830,
                    "name": "PARP Inhibitor (Pan)",
                    "profileName": "POLB loss"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}